Skip to main content

Development and validation of oral chemotherapy self-management scale

Abstract

Background

With the increase of oral chemotherapy drugs, patients receiving cancer treatment prefer oral chemotherapy versus intravenous, given equal efficacy and toxicity. However, they need to take an active part in their care, which is vital with home-based oral therapy, therefore the self-management is important for patients with oral chemotherapy. Unfortunately, the development of self-management assessment tools for oral chemotherapy still lags behind.

Methods

The OCSMS item pool was formulated based on literature review and semi-structured interviews, An initial scale containing 5 dimensions and 38 items was constructed through research seminar, Delphi survey and pilot testing. To assess the validity and reliability, We recruited 261 patients from cancer hospital in China.

Results

A 36-item scale was developed with five dimensions identified through factor analysis: daily life management, symptom management, medication management, emotional cognitive management and social support. Cronbach’s coefficient Alpha, split-half coefficient, test-retest reliability and S-CVI/UA scores were 0.929, 0.773, 0.966 and 0.833, respectively, indicating that OCSMS has good reliability and validity.

Conclusions

The OCSMS is a valid, reliable measurement method of the self-management ability of patients with oral chemotherapy. The OCSMS shows potential as a tool to ensure the safety of patients with cancer. The OCSMS may help evaluate the effectiveness of interventions to improve the self-management ability of patients.

Peer Review reports

Background

Chemotherapy is one of the most important treatments for cancer, and the route of chemotherapy administration is developing continuously. With the spread of oral chemotherapy agents over the last 15 years, people are choosing oral chemotherapy because it is safe, economical and helps prevent venepuncture [1,2,3]. Patients are likely to choose oral chemotherapy than intravenous chemotherapy even with their same efficacy and toxicity [4].

With oral anticancer agents becoming widely common, a critical shift has occurred from clinic-based healthcare provider-administered management to home-based self-administered management [5]. However, it also brings new challenges. For example, patients at home can’t recognize the undesirable side effects, such as nausea and vomiting [4, 6]. Hence, the patient’s self-management ability is very important.

Self-management was proposed by Corbin and Straus for chronic disease [7] and has been defined as managing symptoms, treatments, lifestyle alterations and psychosocial consequences of health conditions [8]. Self-management has been widely used in all aspects of management. Numerous studies have shown that enabling effective self-management of medication in non-malignant chronic diseases (i.e.,Hypertension) results in better disease control and a better quality of life [9, 10]. Self-management is particularly important for patients with oral chemotherapy because it affects their adherence to the treatment, quality of life and safety [11, 12]. To date, no effective evaluation tools have been designed to measure self-management for oral chemotherapy. The purpose of this study is to develop a valid and reliable instrument oral chemotherapy self-management scale (OCSMS).

Methods

This study is a prospective, mixed-method scale development of oral chemotherapy self-management scale (OCSMS). Figure 1 describes the development of this scale.

Fig. 1
figure1

Development of Oral Chemotherapy Self-management Scale

Ethical approval

This study was approved by the medical ethics committee of ZheJiang Cancer Hospital, Hangzhou, Zhejiang, China (IRB-2015-208).

Item generation

Literature review and semi-structured interviews were conducted to generate an item pool. A comprehensive literature review was performed to generate a semi-structured interview guide, which was used for in-depth interviews [13]. Purpose sampling was adopted, involving 10 experts (including nurses, doctors and pharmacists) and 9 patients. Data were analysed using Nvivo11 software. A total of seventy-eight items and six domains of oral chemotherapy self-management were generated.

Research seminar

A total of seventy-eight items and six domains were scrutinized during two-round research seminar. Eight experts with a titles of deputy senior or above and bachelor’s degree or above and six experts with master’s degree or above and more than 3 years of relevant work experience were selected in the two-round research. Thirty items and four domains of oral chemotherapy self-management were chosen in the two-round research seminar.

Delphi survey

Two rounds of Delphi consultation were conducted. Eighteen experts (nurses, doctors and pharmacists) from eight provinces, including Shanghai, Beijing, Zhejiang and Hunan, were invited to evaluate the scale format and each item. All experts have a bachelor’s degree and more than 10 years of relevant work experience. They read, evaluated and rated each item based on its clarity, uniqueness and relevance to oral chemotherapy self-management. Items with a coefficient of variation > 0.25 and average score < 3.5 were removed [14, 15]. We had removed one item, and had added nine items and one domain of oral chemotherapy self-management by using Delphi method.

Additional information on this study design, data analysis and results of literature review and Delphi survey can be found in previous publications [15, 16].

Pilot testing

Prior to undertaking the psychometric properties of the scale, we recruited 40 participants (20 females) for pilot testing. The mean age of 40 participants from Zhejiang Cancer hospital was 53.05 ± 10.68 years (range 27–73 years). The purpose of the pilot testing is to find possible administration problem, such as miss-phrasing, and to determine which items should be modified, added or removed. The researchers explained the purpose of the study, and gave an example before its completion for each participant. After the patients completed the scale, the researchers asked the patients whether they unable to respond. Through the pilot testing, we modified two items without adding or removing any items.

Validity and reliability

To evaluate the psychometric properties of the scale, we recruited 261 participants from Zhejiang Cancer hospital in China between May 12,018 and January 312,019. The minimum sample size for factor analysis should be five times the number of items with at least 200 cases [17]. For the test–retest reliability evaluation of the scale, 40 of the participants returned 2–5 weeks later to complete the same survey. Two participants withdrew from the study. The inclusion criteria were as follow: adults (more than 18 years old) with confirmed diagnosis of cancer, using an oral chemotherapy regimen, willing to participate, and able to communicate using Mandarin. The exclusion criterion was inability for self-care.

Results

Characteristics of the participants

The mean age of participants was 54.78 years (min = 27, max = 83). Among them, 59.4% were male, and 90.4% were married. Table 1 shows their selected demographic characteristics.

Table 1 Demographic Characteristics of the Study Participants

Validity of the scale

We removed two items through exploratory factor analysis. The value of KMO was 0.886, and the result of Barlett’s sphericity test was X2 = 7106.941 (df = 630, p = 0.000). These values indicated that the items of the scale were appropriate for factor analysis. The structure validity of the scale was evaluated with principal components analysis using Varimax rotation. Factors with eigenvalues > 1 were selected. Figure 2 shows that eigenvalues slightly decreased after component 5. Five sub-dimensions were created and labelled as: daily life management (8 items), symptom management (6 items), medication management (11 items), emotional cognitive management (7 items) and social support (4 items). The cumulative explained variance rate of the scale was 63.603%, and the item factor loadings was 0.530–0.903 (Table 2).

Fig. 2
figure2

Scree Plot

Table 2 Item Factor Loadings

A four-point (1 = not relevant, 2 = weak relevant, 3 = strong relevant, 4 = very relevant) ordinal rating scale was used. The Scale-level CVI/ universal agreement (S-CVI/UA) and the item-level CVI (I-CVI) of scale were calculated. According to the number of votes that each item received from the panel of 6 experts, S-CVI/UA was 0.833 and I-CVI of scale ranged from 0.833 to 1(Table 3). The value of S-CVI/UA > 0.8 and I-CVI 0.78 mean good content validity.

Table 3 Experts’ Ratings and CVI Calculation (N = 6)

Reliability of the scale

The internal consistency coefficient “Cronbach’s Alpha” of total scale was 0.929 with the Cronbach’s Alpha of each factor at 0.664–0.927. The split-half coefficient of the total scale was 0.773 with the split-half coefficient of each factor at 0.584–0.919 (Table 4). The test-retest reliability of the total scale was r = 0.966, which was statistically significant and indicated that the scale had good stability over time.

Table 4 Cronbach’s Alpha and Split-half Coefficient of each Domain

Discussion

Reliability and validity of the scale

The OCSMS exhibited good reliability and validity in a clinical sample of patients with oral chemotherapy. We calculated the Cronbach’s Alpha to evaluate the unidimensionality of a set of items. The Cronbach’s Alpha of OCSMS was 0.929, suggesting that the items have relatively high internal consistency. The split-half coefficient and test–retest reliability were also high, implying that the OCSMS has good reliability.

The CVI of OCSMS was quite high, indicating that its items adequately represent the construct being measured. Factor analysis of the OCSMS revealed that the five sub-dimensions accounted for 63.603% of the total variance.

Sub-dimensions of scale

Some scholars believe that oral chemotherapy has the advantages of convenience and tolerance; however, its side effects still need to attract the attention of medical workers [18]. In the interview of this study, patients with cancer receiving oral chemotherapy reported that the most important thing is the lack of professional guidance, especially on adverse symptoms and medications. Therefore, the sub-dimensions of scale include symptom and medication management. Another is that patients have negative emotions, which may be related to the high mortality rate of the tumour. Negative psychology can induced the disease to deteriorate. Therefore, the indicators of this study include emotional cognitive management. On the basis of literature review and expert panel, five sub-dimensions were finally labelled as: daily life management, symptom management, medication management, emotional cognitive management and social support.

Implications for clinical practices

Oral cancer therapies have several advantages, including great flexibility and convenience for the patient and minimal disruption of daily activities [19]. However, some shortcomings, such as the need to self-manage drugs and identify adverse drug reactions, are also noted. Therefore, the patients’ self-management ability is important. Lack of self-management can lead to adverse consequences that may affect therapeutic outcomes and patients [20]. Existing research focused on patient’s compliance [21,22,23]. Prior to this study, no instrument has been designed to assess the self-management ability of patients with oral chemotherapy. A qualitative study [24] showed that self- management should be assessed for patients with oral chemotherapy; hence, a tool for this aspect must be developed. Nurses can give proper health education to patients with poor self-management ability. This tool could be used to ensure the safety of patients with cancer receiving oral chemotherapy at home.

Study limitations

Our study has a number of limitations. First, The research was conducted only in China. Cross-cultural validation studies are necessary. Second, Although the OCSMS was found to have a five-factor structure and good reliability, more research is needed to establish its concurrent or convergent validity or discriminant validity. Third, The sample size (n = 261) was 6.87 times the number of items (38 times), so further studies with larger sample size is required to validate the OCSMS.

Conclusion

The OCSMS has high reliability and validity and takes only a few minutes to complete. Patients with cancer receiving oral chemotherapy reported that this scale is easy to take and can evaluate their self-management ability.

Availability of data and materials

All data supporting the findings are included in this publication.

Abbreviations

OCSMS:

Oral chemotherapy self-management scale

KMO:

Kaiser-meyer-olkin

CVI:

Content validity index

S-CVI/UA:

Scale-level CVI/ universal agreement

I-CVI:

Item-level CVI

References

  1. 1.

    Catania C, Didier F, Leon ME, et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat. 2005;92(3):265–72.

    CAS  PubMed  Google Scholar 

  2. 2.

    Simons S, Ringsdorf S, Braun M, et al. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer. 2011;19(7):1009–18.

    PubMed  Google Scholar 

  3. 3.

    Johnson TM. Long-term care: safe drug handling of Oral chemotherapy. Consult Pharm. 2017;32(2):74–83.

    PubMed  Google Scholar 

  4. 4.

    Ribed A, Romero-Jimenez RM, Escudero-Vilaplana V, et al. Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction. Int J Clin Pharm. 2016;38(2):280–8.

    CAS  PubMed  Google Scholar 

  5. 5.

    Komatsu H, Yagasaki K, Yamaguchi T. Effects of a nurse-led medication self-management programme in cancer patients: protocol for a mixed-method randomised controlled trial. BMC Nurs. 2016;15:9.

    PubMed  PubMed Central  Google Scholar 

  6. 6.

    Ozdelikara A, Tan M. The effect of reflexology on chemotherapy-induced nausea, vomiting, and fatigue in breast Cancer patients. Asia Pac J Oncol Nurs. 2017;4(3):241–9.

    PubMed  PubMed Central  Google Scholar 

  7. 7.

    Kinney J, Kahana E, Corbin JM, Strauss A. Unending work and care: managing chronic illness at home. San Francisco: Jossey-Bass Pubilshers; 1989.

  8. 8.

    Richard AA, Shea K. Delineation of self-care and associated concepts. J Nurs Scholarsh. 2011;43(3):255–64.

    PubMed  Google Scholar 

  9. 9.

    Wei C, Nengliang Y, Yan W, Qiong F, Yuan C. The patient-provider discordance in patients' needs assessment: a qualitative study in breast cancer patients receiving oral chemotherapy. J Clin Nurs. 2017;26(1–2):125–32.

    PubMed  Google Scholar 

  10. 10.

    Spoelstra SL, Given BA, Given CW, et al. An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: an exploratory study. Cancer Nurs. 2013;36(1):18–28.

    PubMed  Google Scholar 

  11. 11.

    Persell SD, Karmali KN, Lee JY, et al. Associations between health literacy and medication self-management among community health center patients with uncontrolled hypertension. Patient Prefer Adherence. 2020;14:87–95.

    PubMed  PubMed Central  Google Scholar 

  12. 12.

    Persell SD, Karmali KN, Lazar D, et al. Effect of electronic health record-based medication support and nurse-led medication therapy management on hypertension and medication self-management: a randomized clinical trial. JAMA Intern Med. 2018;178(8):1069–77.

    PubMed  PubMed Central  Google Scholar 

  13. 13.

    Peng Q, Wu WY. A study on status and demand of Oral chemotherapy self-management among Cancer patients at home. Chin J Rural Med Pharm. 2020;27(14):31–2.

    Google Scholar 

  14. 14.

    Wang SN, Dong R, Xie H, et al. Delphi method and its application Progress in constructing index system. J Bengbu Med Coll. 2019;25(10):1233–7.

    Google Scholar 

  15. 15.

    Peng Q, Wu WY, Liang GM, et al. Construction of self-management assessment indicators for cancer patients with oral chemotherapy at home. Chin J Mod Nurs. 2019;25(10):1233–7.

    Google Scholar 

  16. 16.

    Peng Q, Yu XY, Wu WY. Review of oral anticancer chemotherapeutic agents regulation mode among community-dwelling cancer patients. Chin J Mod Nurs. 2018;24(26):3214–6.

    Google Scholar 

  17. 17.

    MacCallum RC, Widaman KF, Zhang S, Hong S. Sample size in factor analysis. Psychol Methods. 1999;4(1):84–99.

    Google Scholar 

  18. 18.

    May P, LaPlant K, McGee A. Practice model: establishing and running an Oral chemotherapy management clinic. Asia Pac J Oncol Nurs. Oct-Dec 2017;4(4):299–303.

    PubMed  PubMed Central  Google Scholar 

  19. 19.

    Schneider SM, Adams DB, Gosselin T. A tailored nurse coaching intervention for oral chemotherapy adherence. J Adv Pract Oncol. 2014;5(3):163–72.

    PubMed  PubMed Central  Google Scholar 

  20. 20.

    Wong SF, Bounthavong M, Nguyen C, Bechtoldt K, Hernandez E. Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am J Health Syst Pharm. 2014;71(11):960–5.

    PubMed  Google Scholar 

  21. 21.

    Jacobs JM, Ream ME, Pensak N, et al. Patient experiences with Oral chemotherapy: adherence, symptoms, and quality of life. J Natl Compr Cancer Netw. 2019;17(3):221–8.

    Google Scholar 

  22. 22.

    Allen J, Williamson S. Over compliance with capecitabine oral chemotherapy. Int J Clin Pharm. 2014;36(2):271–3.

    CAS  PubMed  Google Scholar 

  23. 23.

    Dowling M, Hunter A, Biesty L, et al. Driving and disabling factors of noncurative Oral chemotherapy adherence: a qualitative evidence synthesis. Oncol Nurs Forum. 2019;46(1):16–28.

    PubMed  Google Scholar 

  24. 24.

    Morris M, Marshall-Lucette S. The experience of myeloma caregivers during home-based Oral chemotherapy treatment: a qualitative study. Semin Oncol Nurs. 2017;33(3):362–71.

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors gratefully acknowledge the study participants and the hospital staff.

Funding

This work was supported by Zhejiang Province Health Medicine Science and Technology Backbone Platform Project (2016RCA004), Youth research fund project of Zhejiang Cancer Hospital (QN201804) and Zhejiang Province Health Medicine Science and Technology Plan Project (2020KY082). The funding body played no role in the design of study, collection, analysis and interpretation of data, or in writing the manuscript.

Author information

Affiliations

Authors

Contributions

QP wrote the manuscript, analyzed the data.wyw contributed to the revision of the manuscript and data collection. All authors have reviewed the manuscript and given final approval of the version to be published.

Corresponding author

Correspondence to Wanying Wu.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the medical ethics committee of ZheJiang Cancer Hospital, Hangzhou, Zhejiang, China. Patients provided their written informed consent prior to responding to the research.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Peng, Q., Wu, W. Development and validation of oral chemotherapy self-management scale. BMC Cancer 20, 890 (2020). https://doi.org/10.1186/s12885-020-07404-0

Download citation

Keywords

  • Cancer
  • Oral chemotherapy
  • Self-management
  • Validation